Financial Performance - Revenue for the six months ended June 30, 2022, was HKD 655,825,000, a decrease of 11.1% compared to HKD 737,374,000 for the same period in 2021[10]. - Gross profit for the period was HKD 586,644,000, down 5.8% from HKD 622,694,000 year-on-year[10]. - The company reported a net profit of HKD 139,231,000, representing a decline of 14.1% from HKD 162,186,000 in the previous year[10]. - The total comprehensive income for the six months ended June 30, 2022, was HKD 46,030,000, compared to HKD 180,212,000 for the same period in 2021, representing a decrease of approximately 74.5%[14]. - Cash generated from operating activities for the six months ended June 30, 2022, was HKD 180,085,000, down from HKD 205,156,000 in the previous year, indicating a decline of about 12.2%[16]. - The reported profit before tax for the six months ended June 30, 2022, was HKD 162,701,000, compared to HKD 183,074,000 for the same period in 2021, representing a decrease of approximately 11.5%[26]. - The group recorded a consolidated revenue of approximately HKD 655.8 million for the six months ended June 30, 2022, a decrease of 11.1% compared to the same period last year[117]. - The group's profit decreased by 14.2% to approximately HKD 139.2 million, down from approximately HKD 162.2 million in the same period last year, primarily due to COVID-19 restrictions impacting outpatient operations in Chinese hospitals[118]. Assets and Liabilities - Total assets as of June 30, 2022, amounted to HKD 2,794,303,000, a decrease from HKD 2,863,439,000 at the end of 2021[12]. - Current liabilities decreased to HKD 621,173,000 from HKD 689,585,000, indicating improved liquidity management[12]. - The total liabilities decreased from HKD 1,742,906,000 as of June 30, 2021, to HKD 1,577,353,000 as of June 30, 2022, indicating a reduction of approximately 9.5%[14]. - The company’s cash and cash equivalents stood at HKD 641,136,000, down from HKD 671,336,000 at the end of 2021[12]. - The company’s total liabilities decreased from HKD 1,259,471,000 as of December 31, 2021, to HKD 1,422,203,000 as of June 30, 2022, indicating a change in financial structure[30]. - The debt-to-asset ratio as of June 30, 2022, was 37.6%, a decrease from 39.4% as of December 31, 2021, reflecting improved financial stability[137]. Cash Flow and Investments - The net cash used in investing activities for the six months ended June 30, 2022, was HKD 143,617,000, compared to HKD 119,463,000 in the same period of 2021, reflecting an increase of approximately 20.2%[18]. - The company reported a decrease in cash and cash equivalents of HKD 7,813,000 for the six months ended June 30, 2022, compared to an increase of HKD 52,673,000 in the same period of 2021[18]. - The company has capital commitments of 73,814,000 HKD for development costs and 211,251,000 HKD for acquired intangible assets as of June 30, 2022[94]. - The company secured bank financing of approximately HKD 629.7 million, with around HKD 505.8 million already utilized as of June 30, 2022[137]. Shareholder Information - The company paid dividends amounting to HKD 31,610,000 during the six months ended June 30, 2022[18]. - The company declared an interim dividend of HKD 0.04 per ordinary share for the six months ended June 30, 2022, consistent with the previous year[40]. - The company aims to enhance shareholder value through share repurchases to improve net asset value per share and earnings per share[187]. - Major shareholders include Yan Ming Chi with 153,945,667 shares (26.81%) and Liu Hui Juan with 153,945,667 shares (26.81%) as of June 30, 2022[176][183]. Research and Development - Research and development costs recognized as expenses amounted to HKD 11,606,000 for the six months ended June 30, 2022, compared to HKD 11,080,000 for the same period in 2021[36]. - The group has initiated a five-year R&D plan (2021-2025) to enhance its R&D capabilities and position in the ophthalmology field[110]. - The group has 15 R&D projects in various stages, with three ophthalmology projects currently in clinical stages, viewed as mid-term growth drivers[112]. Market and Product Development - The estimated number of moderate to severe dry eye patients in China exceeded 117 million in 2019, indicating a significant market potential for the SkQ1 product[103]. - The estimated number of patients for the four types of conditions treatable by the anti-VEGF licensed product in China exceeded 15.5 million in 2019[105]. - The bFGF product series accounted for approximately 86.5% of the total revenue during the review period[98]. Corporate Governance - The company maintained compliance with the corporate governance code throughout the review period[189]. - All directors confirmed compliance with the code of conduct regarding securities trading for the six months ended June 30, 2022[194].
亿胜生物科技(01061) - 2022 - 中期财报